Acceptance Limits for the New ICH USP 29 Content-Uniformity Test - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Acceptance Limits for the New ICH USP 29 Content-Uniformity Test
Revisions to the United States Pharmacopeia's (USP) uniformity test require manufacturers to establish new acceptance limits. The authors present their method for calculating acceptance limits consistent with USP's revised content-uniformity test requirements.


Pharmaceutical Technology


Where k = 2.4 for n = 10; k = 2.0 for n = 30; s is the standard deviation of the observations.

Unless otherwise specified, all the measurements of dosage units and criteria values (such as L 1) are in percentage label claim.

Lower probability bound of passing USP

Notice that P(passing USP test)



Assume that the X i 's follow a normal distribution denoted N (μ, σ). Then the values of P(S 1) and P(S 2) can be calculated as described in the following two subsections.

Computation of P(S 1)

Given the definition of AV, it can be seen that:

For T ≤ 101.5



The density function of Z 2 is a x2 distribution with n – 1 degrees of freedom and is denoted as x2 (n – 1).

The joint density function is f(z 1,Z 2) = f 1(z 1) f 2(Z 2),

Given the independence of z 1 and Z 2, P(S 1) can be rewritten in terms of z 1 and Z 2 as:





Computation of P(S 2)

There are two subcriteria in S 2, which are denoted as C 21 and C 22, respectively, as follows:

C 21 = AV of the 30 dosage units is less than or equal to L 1.

C 22 = no unit deviates from the calculated value of M by more than 25% of M.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
21%
Do not use QbD
18%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here